Your browser doesn't support javascript.
loading
Severe loss of appetite and refusal to eat as severe side effect of glycerol phenylbutyrate.
Grünert, Sarah Catharina; Schumann, Anke; Spiekerkoetter, Ute.
Affiliation
  • Grünert SC; Department of General Pediatrics, Adolescent Medicine and Neonatology Medical Center-University of Freiburg, Faculty of Medicine Freiburg Germany.
  • Schumann A; Department of General Pediatrics, Adolescent Medicine and Neonatology Medical Center-University of Freiburg, Faculty of Medicine Freiburg Germany.
  • Spiekerkoetter U; Department of General Pediatrics, Adolescent Medicine and Neonatology Medical Center-University of Freiburg, Faculty of Medicine Freiburg Germany.
JIMD Rep ; 63(6): 521-523, 2022 Nov.
Article in En | MEDLINE | ID: mdl-36341170
Glycerol phenylbutyrate (GPB) is an ammonia scavenger drug commonly used in the therapy of patients with urea cycle defects. Reported side effects include body odor, abdominal pain, nausea, burning sensation in mouth, vomiting, and heartburn. We report on a 3-year-old late diagnosed female patient with ornithine transcarbamylase deficiency that experienced severe loss of appetite under treatment with GBP. Due to catabolism (calory intake about 400 kcal/day) and the associated risk of metabolic decompensation, GBP treatment was discontinued. Her appetite and eating behavior normalized within 1 day after discontinuation of GBP and switch to sodium benzoate. Our case demonstrates that GBP can cause severe loss of appetite that may put patients at risk of metabolic decompensation and require discontinuation of therapy.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: JIMD Rep Year: 2022 Document type: Article Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: JIMD Rep Year: 2022 Document type: Article Country of publication: United States